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Abstract  5 
Purpose: To estimate the incidence and predisposing factors for cataract extraction (CE) after 6 
Deep Sclerectomy (DS) and its effect on intraocular pressure (IOP) control 7 
Methods: Retrospective study of all phakic eyes which had DS performed over a 5-year period 8 
and after exclusions, 244 eyes of 244 patients were included. 9 
Results: The mean age at time of DS was 69.6 ± 9.6 years and the mean follow-up was 85.9 ± 10 
30.6 months. In the follow-up period, 93 eyes (38.1%) had CE.  The probability of CE was 2.5% 11 
at 1, 16.4% at 3, 26% at 5 and 38% at 7 years with a median survival time of 115 months.  12 
Multivariate analyses showed that age (Hazard ratio 1.06, 95% CI 1.04- 1.08, p<0.0001) and 13 
Needle Revision with Mitomycin C (HR 1.8, 95% CI 1.1- 3.0, p= 0.03) had a significant association 14 
with CE after DS. The mean IOP before cataract surgery was 11.6 ±4.5 mmHg and increased 15 
significantly (p < 0.001) at all measured time-intervals up to a year after cataract surgery.  16 
Number of eyes on glaucoma medications before CE was 8 (mean 0.16 ± 0.5) and by last follow-17 
up, 15 eyes were on medications (mean 0.37 ±0.8, p=0.01).  Post-CE needle revision was 18 
performed on 7 eyes (7.5%).  19 
Conclusions: The actuarial probability of cataract surgery after DS is low, with a gradual 20 
increase with time. Increasing age and needle revision were found to be statistically significant 21 
risk factors. There was a modest increased IOP after CE and increase use of glaucoma 22 
medications.  23 
 24 
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Title: Cataract Extraction after Deep Sclerectomy and its Effect on Intraocular 26 
Pressure Control 27 
Introduction 28 
Cataract is commonly observed following trabeculectomy. The incidence of cataract extraction 29 
(CE) is between 20-52 %, 2-7 years after trabeculectomy(1-6), and is higher than in age-30 
matched controls on glaucoma medications(7, 8). CE following trabeculectomy confers greater 31 
risks (2), and is associated with increased risk of bleb failure(1, 9-13). 32 
In Deep Sclerectomy (DS), a thin outer scleral flap is maintained and loosely sutured to allow 33 
subconjunctival space filtration with bleb formation(14). A permeable filtration membrane (the 34 
trabeculo-Descemet’s membrane - TDM) is created which provides aqueous-outflow resistance 35 
and reduces postoperative change in the anterior chamber. A peripheral iridectomy is not 36 
performed. Laser goniopuncture (LGP) and needling is performed to manage delayed 37 
intraocular pressure (IOP) rise(15, 16). Mitomycin-C (MMC) is routinely used to enhance bleb 38 
formation and achieve low target intraocular pressures (IOP) (17). A meta-analysis concluded 39 
that the absolute risk of surgically-induced cataract is lower in non-penetrating glaucoma 40 
surgery (NPGS) compared to trabeculectomy(18), and that the progression of cataract occur in 41 
1-25% of eyes up to five-years following DS(19-21). However, none of these studies report 42 
actuarial probability of CE after DS.  43 
In this study, we investigate the long-term actuarial probability and predisposing factors for CE 44 
following DS and the effect of CE on IOP control.  45 
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Methods 46 
A retrospective, non-randomised, case-note review of all patients who underwent DS which 47 
were performed or supervised by a consultant surgeon (NA) over a 5-year period, between 48 
August 2001 to August 2006, in Calderdale and Huddersfield NHS Trust was performed. All 49 
patients were identified from a correlational ongoing database (Microsoft Access). The 50 
database was analysed for phakic DS on eyes with primary open angle, pigmentary and 51 
pseudoexfoliative glaucoma.  52 
Data collected included demographics, Snellen BCVA, IOP, bleb characteristics, post-operative 53 
complications, interventions and medications.  54 
A standardised operative technique and postoperative management was used, which have 55 
been described previously(15-17). Phacoemulsification was done avoiding the DS site. 56 
Postoperatively, a topical steroid-antibiotic combination was prescribed for 4-8 weeks. 57 
Subconjunctival  bleb observations were made by a single observer (NA) using the Indiana Bleb 58 
Appearance Grading Scale(22). Bleb failure was defined as a decrease in the bleb extent by ≥2 59 
grades. Failure of DS was defined as an increase in number of glaucoma medications, bleb-60 
needling, or further glaucoma surgery to maintain IOP control (9, 23). LGP or iridoplasty was not 61 
considered as failure. 62 
Medcalc® (8400 Ostend, Belgium) was used for statistical analyses. Kaplan-Meier-Survival 63 
outcomes were calculated to establish the probability of CE after DS and IOP-control after CE. 64 
Cox’s-regression-analysis was done to investigate survival curves. IOP changes after CE were 65 
analysed by repeated-measures-ANOVA and Kiskal-Wallist test was used to determine visual 66 
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acuity changes. The Mann-Whitney-U-test was used to determine the change in the number of 67 
glaucoma medication. The Chi-squared-test with Yates-correction and Fisher’s exact test were 68 
used for categorical data. P<0.05 were statistically significant.  69 
Results 70 
342 eyes were identified. 98 eyes were excluded due to age <40 years (8 eyes), repeat 71 
glaucoma surgery before CE (21 eyes), follow-up <1 year (12 eyes) and second eye in bilateral 72 
cases (57 eyes). 244 eyes of 244 patients were included for final analyses. 73 
Baseline characteristics are shown in Table 1. Mean follow-up after DS was 85.9± SD30.6 74 
months. 93 patients had CE. Patients who had CE after DS were older. Peripheral iridectomy 75 
was performed in 8 eyes with perforation, of which 3 eyes had subsequent CE. CE was 76 
performed in 5 eyes with hypotony i.e. IOP < 5 mmHg.  77 
DS complications and post-operative procedures are shown in Table 2. Eyes which had 78 
undergone needle revision and laser iridoplasty were more likely to eventually have CE. 56 eyes 79 
had IOP<10mmHg following DS, of which 26 eyes had CE (p=0.31). 80 
CE was performed within the first year after DS in 6 eyes (2.5%). One patient was originally 81 
intended for a combined phaco-DS procedure but underwent a sequential procedure instead 82 
due to inability to tolerate the duration of the procedure. The probability of CE increases with 83 
duration following DS and the 50% probability (median survival time) for CE after DS was 115 84 
months (9.6 years). (Figure 1A). Cox’s-regression-analyses showed a significant influence of age 85 
(Hazard-ratio1.06,95%CI1.04-1.09,p<0.001) and needle-revision (Hazard-ratio1.8,95%CI1.1-86 
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3.0,p=0.03) on the probability of CE (Table 3). There was no significant difference in IOP 87 
between eyes which remained phakic and those which had subsequent CE (ANOVA p=0.9) 88 
(Figure 1B).  89 
Complications and procedures after CE are shown in Table 4. Mean follow-up after CE was 47.6 90 
±28.3months (range 4-112months). 76-eyes completed 1-year, 62-eyes more than 2-years 91 
(75.6%) and 45 had more than 3-years of follow-up (52.9%). The probability of failure was 21% 92 
at 2-years and 26% at 4-years (Figure 1C). In all, 18 eyes failed with bleb failure in 4-eyes and 93 
there was no significant association with age, LGP, MMC-use, pre-CE needle revision and pre-CE 94 
IOP of <11mmHg (Cox’s regression model;p>0.05). 10 with hypotony (IOP <6mmHg) prior to CE 95 
had no effect on failure (Univariate survival analyses; p=0.09). A pre-CE IOP of ≥11 mmHg had a 96 
significant negative-association with failure with univariate log-rank test (p=0.002) but not by 97 
the Cox’s regression analyses (p=0.06). Only 2 of 36 eyes with a pre-CE IOP<11mmHg were 98 
deemed failures.  99 
The mean IOP before CE was 11.6±4.5mmHg and increased significantly (p<0.001) up to a year 100 
after CE (Figure 1D). Repeated-measures ANOVA models show no significant difference for 101 
changes in IOP after CE up to 2, 3 and 4 years. Number of eyes on glaucoma medications before 102 
CE was 8 (mean 0.16 ± 0.5) and by last follow-up was 15 eyes (mean 0.37 ±0.8,p=0.01). Post-CE 103 
needle revision was performed in 7 eyes (7.5%) and was successful in lowering IOP by >30% in 104 
all eyes till last follow-up.  105 
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In all, 15 eyes lost ≥2 Snellen VA lines during follow-up (Figure 1E). The causes for the reduction 106 
in vision were ARMD(n=5), glaucoma progression(n=2), endopthalmitis(n=1), CRVO(n=1), 107 
diabetic maculopathy(n=1) and unknown(n=5). 108 
Discussion 109 
Previous studies investigating the prevalence of CE following NPGS were limited by small 110 
numbers, short follow-ups, and no Kaplan-Meier probabilities for CE. Lachkar-et-al noted that 111 
17 of 179 patients underwent CE following DS with a mean follow-up of 54 months(19). 112 
Shaarawy-et-al, with a mean follow-up of 64 months, noted progression of a pre-existing 113 
cataract in a quarter of patients’(21). Our study with a mean follow-up time of over 7-years, 114 
found the probability of CE to be quite low, approximately 2.5% in the first year and gradually 115 
increasing with time. Older age at time of DS was positively correlated with risk for CE. 116 
The incidence of CE varied from 21.5% at 7.5 years after trabeculectomy in the CIGTS (mean age 117 
58-years) to almost 50% at 5-years in the AGIS(2). Trabeculectomy is more likely to cause 118 
cataract than medical or laser therapy for glaucoma(24, 25). A surgical iridectomy may decrease 119 
aqueous flow across the lens and disrupt mechanisms that preserve transparency. Additionally, 120 
postoperative inflammation and hypotony may increase the risk of cataract(2). Chiou-et-al 121 
found less postoperative inflammation in DS(26) and Rulli-et-al showed less postoperative 122 
complications in NPGS(18). The anterior chamber is more stable and the aqueous dynamics are 123 
not modified in NPGS.  124 
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The use of MMC to enhance subconjunctival aqueous flow, may be associated with an 125 
increased risk of cataract in trabeculectomy, and may be toxic to the lens epithelium(27). LGP 126 
and needle revision effectively convert DS to trabeculectomy and delayed hypotony may occur 127 
in cases where MMC was used(17). No statistical significant link with MMC use and CE was 128 
identified in our 244 patients with DS. However, a statistically-significant association was 129 
observed in patients requiring MMC needle revision (relative risk 1.7,p=0.03), and may be due 130 
to potential exposure to subconjunctival MMC. 131 
AGIS reported a higher incidence of cataract in trabeculectomy eyes with early postoperative 132 
inflammation and flat anterior chambers(2). Our results suggest that intraoperative 133 
macroperforation and conversion into a guarded fistula, may be associated with an increased 134 
risk of subsequent cataract. However, this association did not meet statistical significance 135 
(p=0.08). We did not find an association between hypotony and cataract formation following 136 
DS.  137 
Age is another risk-factor for cataract following trabeculectomy. In AGIS, the mean age was 65-138 
years for patients undergoing CE compared to 55-years for those who didn’t. The cataract risk 139 
in AGIS increased by 7% for a 1-year increase in age compared to 6% in this study(2, 24). A UK-140 
audit reported that 111 of 376 phakic eyes required CE following trabeculectomy. The mean 141 
age of the trabeculectomy cohort was 69.5-years and mean follow-up was 40 months(28). In 142 
this study, 93 of 244 patients with DS underwent CE with a mean follow-up of 86 months. It 143 
would therefore appear that the age-adjusted risk of CE after DS may be similar to that of 144 
uncomplicated trabeculectomy.  145 
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A prospective study from Spain on IOP changes after phacoemulsification in trabeculectomy 146 
eyes reported that the mean IOP increased from 12mmHg to 16mmHg for the first 3 months 147 
after CE. The mean IOP then maintained between 14-15mmHg for the next 2 years, and that 148 
65.3% of patients did not need medication to maintain IOP control at 2 years post surgery. The 149 
failure rate (with addition of medication, bleb needle revision or further IOP surgery) was 44% 150 
at 2years. They also noted a reduction in bleb size in 77.6% eyes by the last visit after 151 
surgery(9). Two retrospective studies on CE after trabeculectomy with similar failure criteria 152 
and follow-ups (less than 2 years) reported failure rates of 23-26%(23, 29). The IOP changes in 153 
our study were remarkably similar to Rebolleda et al(9). There was an initial increase in mean 154 
IOP by 3-4 mmHg, followed by a decline of 2mmHg after 6 weeks. This decline after 6 weeks 155 
may be due to addition of glaucoma medication, bleb-needling or a decrease in inflammation. 156 
In our study, at last follow-up, 83% were not on glaucoma medications and the failure rate was 157 
21% at 2 years and 26% at 4 years. We noted a significant decrease in bleb size in 4.8%. 7 eyes 158 
needed needle revision, presumably due to bleb failure. Hence, it would appear that IOP 159 
changes after CE in DS are broadly similar to that expected to trabeculectomy. It is likely that 160 
the inflammatory response elicited by CE induces subconjunctival scarring and IOP elevation. 161 
Postoperative inflammation after phacoemulsification (measured by a flare meter) remains 162 
significantly higher than baseline for 3 months(30).  163 
The current study has several limitations. It is retrospective, lacks a control group, and there is 164 
no differentiation between age-related and surgically-induced cataract progression. 165 
Comparison with cataract progression after trabeculectomy is difficult due to differing criteria 166 
for cataract progression. For example, in AGIS (2), cataract progression was defined as having 167 
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CE or confirmed severe lens opacity with a ETDRS BCVA score <65 letters. The indication for CE, 168 
in this study, is based on patient-reported decrease in vision and may underestimated the ‘true’ 169 
probability of cataract progression. Information was not collated on potential systemic 170 
disorders which may increase the risk of cataract formation such as diabetes. These results 171 
cannot be extrapolated to other types of NPGS, where LGP and needle revision are not 172 
routinely performed.  173 
In summary, this is the largest study describing the incidence of CE following DS and its effect 174 
on IOP. The probability of CE gradually increases from 2.5% in the first year to 38% by 7 years. 175 
Older patients at time of DS and postoperative manipulations, which may convert the DS to a 176 
fistulising procedure and possibly exposure to MMC may increase the incidence of CE. CE has 177 
an adverse effect on IOP, which is similar to other bleb forming procedures.    178 
179 
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Figure Legend  267 
Figure 1A. Kaplan-Meier graph showing the probability of cataract extraction after Deep 268 
Sclerectomy (95% confidence intervals). The probability of cataract extraction was 2.5% at 1 269 
year, 16.4% at 3 years, 26% at 5 and 38% at 7 years.  270 
Figure 1B. Interval change in mean intraocular pressure after deep sclerectomy comparing eyes 271 
which required phacoemulsification to eyes which remained phakic (with 95% confidence 272 
intervals). Abbreviation: PreDS= IOP prior to DS, M=month, Y=year  273 
Figure 1C. Kaplan-Meir probability of failure after phacoemulsification in eyes with previous 274 
deep sclerectomy (95% confidence intervals) 275 
Figure 1D. The effect of phacoemulsification on DS. Graph showing the change in intraocular 276 
pressure following phacoemulsification. Error bars are 95% confidence intervals. 12 eyes were 277 
excluded from IOP change analyses for the following reasons: follow-up < 3 months (n=2), 278 
subsequent corneal graft (n=1), simultaneous bleb revision for hypotony (n=5) and combined 279 
cataract and glaucoma surgery (trabeculectomy (n=1), DS revision (n=1) and needle revisions 280 
(n=2). Abbreviation: W=week. M= month, Y=year 281 
Figure 1E.  The change in vision phacoemulsification in deep sclerectomy. Snellen Visual Acuity 282 
was converted to LogMAR Visual Acuity. Error bars are 95% confidence intervals. Abbreviations: 283 
W=week. M= month, Y=year 284 
285 
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Tables 286 
 All Phakic Cataract p value 
Number 244 151 93  
Age at time of DS (years) 69.6 ± 9.6 68.06 ± 10.4 72.2 ± 7.9 <0.001 
Race 
Caucasian 
African  
Indian 
 
236 
7 
1 
 
148 
3 
0 
 
88 
4 
1 
 
Sex ( Male/Female) 132/112 82/69 50/43 0.9 
Previous interventions 
• Trabeculectomy 
• Deep Sclerectomy with MMC 
• Ectropion Surgery 
• Argon Laser Trabeculoplasty 
• Nd:YAG Laser Iridotomy 
14 
5* 
2 
1 
3 
8 
9 
1 
2 
1 
2 
5 
5 
4 
0 
0 
1 
3 
0.9 
Intraoperative use of Mitomycin-C 210 (86.1%) 132 (87.9%) 78 (83.9%) 0.9 
Intraoperative Perforation of TDM 28 (11.5%) 13 (8.6%) 15 (13.3%) 0.11 
Table 1. Baseline demographics and operative variable.  287 
*1 eye had 2 trabeculectomies and revision of trabeculectomy with MMC 288 
 289 
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 All 
 
Phakic Cataract  p 
Total 244 151 95  
Complications after Deep Sclerectomy 
Shallow anterior chamber 5 3 2  
Conjunctival edge leak 5 3 2  
Choroidal detachment 4 2 2  
Acute IOP rise after perforation or LGP 4 2 2  
Delayed bleb leak 2 1 1  
Blebitis 1 1 0  
Endophthalmitis 1 0 1  
Descemet’s Membrane Detachment 1 0 1  
Bleb dysesthesia requiring bleb excision 1 1 0  
Delayed Hypotony*  11 7 4 0.93 
Procedures after Deep Sclerectomy 
Nd:YAG Laser Goniopuncture 162 97 65 0.78 
Needle Revision with antimetabolite injection 52 24 28 0.03
Nd:YAG and/or Argon Laser Iridoplasty 66 33 33 0.05
Iris Synechiae at TDM 28 14 16 0.15 
17 
 
Table 2.  Complications and procedures after deep sclerectomy but before cataract surgery. * 290 
delayed hypotony refers to IOP <6 mmHg for greater than 6 months or associated with macular 291 
folds). Abbreviation: TDM-Trabecular-Descemet Membrane 292 
 Hazard 
Ratio 
95% confidence 
intervals 
p
Age  1.06 1.04 to 1.09 <0.0001
Female  0.95 0.62 to 1.45 0.80 
Needle Revision with Mitomycin-C 1.78 1.07 to 2.97 0.03 
Intraoperative perforation of TDM 1.74 0.93 to 3.25 0.08 
Postoperative Argon/Nd:YAG laser Iridoplasty 1.36 0.86 to 2.17 0.19 
Laser goniopuncture not performed 1.26 0.74 to 2.15 0.39 
Postoperative IOP < 10 mmHg  (beyond 6 months) 1.11 0.68 to 1.80 0.67 
Intraoperative Mitomycin-C application 1.07 0.60 to 1.91 0.82 
Table 3.  Results of Cox’s Regression Analyses for possible risk factors for cataract surgery after 293 
deep sclerectomy. Abbreviation: TDM = trabecular-Descemet Membrane 294 
295 
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 296 
 Number (%) 
Complications observed during phacoemulsification  
Posterior capsule rupture   2 
Complications observed after phacoemulsification  
Postoperative IOP increase >10 mmHg 5 
Endophthalmitis 1 
Blebitis 1 
Delayed Bleb Leaks 2 
Subluxated IOL 1 
Iris incarceration in perforation/goniopuncture site 2 
Hypotony after Needle Revision 1 
Total Number of Eyes with Complications 14 (15.0%) 
Procedures after Phacoemulsification 
Needle revision  - Total 
5-Fluorouracil 
Topical Mitomycin-C 
Subconjunctival Mitomycin-C 
7 
5 
1 
1 
Anterior Chamber Paracentesis 4 
Revision of DS with subconjunctival Bevacizumab 1 
Trabeculectomy with MMC 1 
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Intravitreal Antibiotics 2 
Intravitreal Bevacizumab 1 
Anterior vitrectomy & surgical removal of iris from perforation of TDM 1 
Ectropion surgery 1 
Subconjunctival autologous blood 2 
Nd:YAG laser goniopuncture 11 
Argon & Nd:YAG Laser Iridoplasty 5 
Selective Laser Trabeculoplasty 3 
Nd:YAG Laser Capsulotomy 2 
Nd:YAG Laser Iridotomy 1 
Argon Laser Panretinal Photocoagulation 1 
Total number of eyes with procedures 29 (31.2%) 
Table 4. Complications during/after phacoemulsification in eyes with prior deep sclerectomy 297 
and subsequent procedures performed 298 
 299 
	
